Literature DB >> 19770585

The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.

John M Heddleston1, Zhizhong Li, Roger E McLendon, Anita B Hjelmeland, Jeremy N Rich.   

Abstract

Glioblastomas are highly lethal cancers that contain cellular hierarchies with self-renewing cancer stem cells that can propagate tumors in secondary transplant assays. The potential significance of cancer stem cells in cancer biology has been demonstrated by studies showing contributions to therapeutic resistance, angiogenesis and tumor dispersal. We recently reported that physiologic oxygen levels differentially induce hypoxia inducible factor-2alpha (HIF2alpha) levels in cancer stem cells. HIF1alpha functioned in proliferation and survival of all cancer cells but also was activated in normal neural progenitors suggesting a potentially restricted therapeutic index while HIF2alpha was essential in only in cancer stem cells and was not expressed by normal neural progenitors demonstrating HIF2alpha is a cancer stem cell specific target. We now extend these studies to examine the role of hypoxia in regulating tumor cell plasticity. We find that hypoxia promotes the self-renewal capability of the stem and non-stem population as well as promoting a more stem-like phenotype in the non-stem population with increased neurosphere formation as well as upregulation of important stem cell factors, such as OCT4, NANOG and c-MYC. The importance of HIF2alpha was further supported as forced expression of non-degradable HIF2alpha induced a cancer stem cell marker and augmented the tumorigenic potential of the non-stem population. This novel finding may indicate a specific role of HIF2alpha in promoting glioma tumorigenesis. The unexpected plasticity of the non-stem glioma population and the stem-like phenotype emphasizes the importance of developing therapeutic strategies targeting the microenvironmental influence on the tumor in addition to cancer stem cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19770585      PMCID: PMC2825672          DOI: 10.4161/cc.8.20.9701

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  73 in total

1.  Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia.

Authors:  Kalindi Parmar; Peter Mauch; Jo-Anne Vergilio; Robert Sackstein; Julian D Down
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-20       Impact factor: 11.205

Review 2.  The transcriptional foundation of pluripotency.

Authors:  Ian Chambers; Simon R Tomlinson
Journal:  Development       Date:  2009-07       Impact factor: 6.868

3.  The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

Authors:  Paraic A Kenny; Genee Y Lee; Connie A Myers; Richard M Neve; Jeremy R Semeiks; Paul T Spellman; Katrin Lorenz; Eva H Lee; Mary Helen Barcellos-Hoff; Ole W Petersen; Joe W Gray; Mina J Bissell
Journal:  Mol Oncol       Date:  2007-06       Impact factor: 6.603

Review 4.  Hypoxia and pluripotency in embryonic and embryonal carcinoma stem cell biology.

Authors:  Unai Silván; Alejandro Díez-Torre; Jon Arluzea; Ricardo Andrade; Margarita Silió; Juan Aréchaga
Journal:  Differentiation       Date:  2009-07-14       Impact factor: 3.880

5.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens.

Authors:  Steven M Pollard; Koichi Yoshikawa; Ian D Clarke; Davide Danovi; Stefan Stricker; Roslin Russell; Jane Bayani; Renee Head; Marco Lee; Mark Bernstein; Jeremy A Squire; Austin Smith; Peter Dirks
Journal:  Cell Stem Cell       Date:  2009-06-05       Impact factor: 24.633

6.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

Review 7.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

8.  SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

Authors:  Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

9.  Hypoxia and HIF1alpha repress the differentiative effects of BMPs in high-grade glioma.

Authors:  Francesca Pistollato; Hui-Ling Chen; Brian R Rood; Hui-Zhen Zhang; Domenico D'Avella; Luca Denaro; Marina Gardiman; Geertruy te Kronnie; Philip H Schwartz; Elena Favaro; Stefano Indraccolo; Giuseppe Basso; David M Panchision
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

10.  Low oxygen enhances primitive and definitive neural stem cell colony formation by inhibiting distinct cell death pathways.

Authors:  Laura Clarke; Derek van der Kooy
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

View more
  350 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

2.  The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.

Authors:  Mei Yee Koh; Robert Lemos; Xiuping Liu; Garth Powis
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

3.  Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype.

Authors:  Kaijie He; Tong Xu; Amir Goldkorn
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

4.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Authors:  Sarah J Conley; Elizabeth Gheordunescu; Pramod Kakarala; Bryan Newman; Hasan Korkaya; Amber N Heath; Shawn G Clouthier; Max S Wicha
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

5.  Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.

Authors:  J M Heddleston; Q Wu; M Rivera; S Minhas; J D Lathia; A E Sloan; O Iliopoulos; A B Hjelmeland; J N Rich
Journal:  Cell Death Differ       Date:  2011-08-12       Impact factor: 15.828

6.  Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain.

Authors:  Matthew D Budde; Eric Gold; E Kay Jordan; Melissa Smith-Brown; Joseph A Frank
Journal:  NMR Biomed       Date:  2011-09-22       Impact factor: 4.044

7.  Nicotinamide metabolism regulates glioblastoma stem cell maintenance.

Authors:  Jinkyu Jung; Leo Jy Kim; Xiuxing Wang; Qiulian Wu; Tanwarat Sanvoranart; Christopher G Hubert; Briana C Prager; Lisa C Wallace; Xun Jin; Stephen C Mack; Jeremy N Rich
Journal:  JCI Insight       Date:  2017-05-18

Review 8.  The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences.

Authors:  Estelle Willems; Arnaud Lombard; Matthias Dedobbeleer; Nicolas Goffart; Bernard Rogister
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

Review 9.  Glioblastoma stem cells: Molecular characteristics and therapeutic implications.

Authors:  Nermin Sumru Bayin; Aram Sandaldjian Modrek; Dimitris George Placantonakis
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 10.  Cytoglobin in tumor hypoxia: novel insights into cancer suppression.

Authors:  Sankalpa Chakraborty; Rince John; Alo Nag
Journal:  Tumour Biol       Date:  2014-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.